Table 8. Comorbidities and conditions for the assessment to choose the second-line TKI.

0 – should avoid, 1 point – preferred, 0.5 – intermediate, ND – no data

TKI, tyrosine kinase inhibitor

Condition Drug	Nilotinib	Dasatinib	Ponatinib	Bosutinib
Coronary artery disease (documented atherosclerotic coronary artery lesion or myocardial infarction in anamnesis) or cerebrovascular disease	0	0	0	1
Peripheral arterial occlusive disease	0.5	1	0	1
A prior venous thrombosis	1	1	0	1
A high/very high cardiovascular risk	0	1	0	1
A heart failure (proBNP, left ventricular dysfunction)	1	1	0	1
Cardiac rhythm alterations (QT prolongation syndromes, Torsades de pointes documented prior, concomitant drugs that prolong QT)	0	1	1	1
An uncontrolled hypertension	1	1	0	1
Pulmonary pleural effusion, pulmonary (lung) disease disorders (e.g. chronic obstructive pulmonary disease)	1	0	1	0.5
Pneumonitis	1	0	1	0
Pre-existing pulmonary hypertension	1	0	1	1
A prior hepatotoxicity	1	1	0	1
A prior hyperbilirubinemia Genotypic (UDP- glucuronyltransferase) – Gilbert syndrome	0	1	1	1
T2DM controlled or prediabetes	1	1	1	1
T2DM uncontrolled	0	1	1	1
Family hypercholesterinemia or high baseline total cholesterol	0	1	0 (TG increase)	1
Hypophosphatemia, hyperparathyroidism	0	0.5	1	1
Hypothyroidism	0	0	1	1
Hematological myelosuppression
Anemia	1	0	0.5	1
Thrombocytopenia	0.5	0	0	0.5
Neutropenia	0.5	0	0.5	0.5
Sepsis, infections complications	1	0	1	1
The bleeding history, gastrointestinal bleeding	1	0	0	1
The Anticoagulation concomitant necessity ( concomitant AF)	1	0	0	1
The antiplatelet therapy necessity	1	0	0	1
Diarrhea	0.5	1	1	0
Pancreatic problems (history of pancreatitis)	0	1	0	1
A reproductive function	1	0	ND	0
A renal failure	1	0.5	0	0
Neurological conditions (headache)	0	0	0	0.5